Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Imlifidase før nyretransplantation hos højsensibiliserede børn (DINKY)

6. november 2026 opdateret af: Hansa Biopharma AB

Et enkeltarms, multicenterforsøg for at evaluere effektiviteten og sikkerheden af ​​imlifidase hos stærkt sensibiliserede børn (1-17 år), der modtager en nyretransplantation med positiv krydsmatch mod en levende eller afdød donor, der er konverteret til negativ efter imlifidase-behandling

The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).

The main questions it aims to answer are:

  • Does imlifidase treatment result in crossmatch conversion that enables transplantation?
  • How is the function of the transplanted kidney?

The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

After being informed about the study and potential risks, all patients giving written informed consent will undergo pre-screening to determine eligibility for study entry.

The trial will include highly sensitised ESRD paediatric patients (1-17 years). The patients have previously undergone desensitization unsuccessfully or have an anti-HLA antibody status deemed too difficult to make a successful desensitization using other experimental methods.

A screening visit will take place when an organ offer has been placed for a final check of the patients' eligibility for study participation.

All patients included in the trial will be desensitized with imlifidase to convert the positive XM to negative and then transplanted with either a kidney from a deceased donor (DD) or a living donor (LD).

Patients will be hospitalised in accordance with the normal routines for transplanted patients at each clinic.

Following transplantation, the patients will receive induction therapies, rejection prophylaxis, and maintenance immunosuppressive therapies.

The patients will be closely monitored for any signs of antibody-mediated rejections (AMRs).

The duration of the interventional trial period after an organ has been offered will be 6 months for each patient. The trial includes a follow-up part to collect long-term efficacy and safety data up to 5 years after the transplantation.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

10

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • London, Det Forenede Kongerige, WC1N 3JH
        • Rekruttering
        • Great Ormond Street Hospital for Children NHS Foundation Trust
        • Kontakt:
          • S Marks, MD
        • Ledende efterforsker:
          • S Marks, MD
      • Helsinki, Finland, 00290
        • Trukket tilbage
        • HUS, Helsinki University Hospital
      • Paris, Frankrig, 75019
        • Rekruttering
        • Robert Debre University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Julien Hogan, Professor
      • Rome, Italien, 00165
        • Ikke rekrutterer endnu
        • Ospedale Pediatrico Bambino Gesu
        • Kontakt:
        • Ledende efterforsker:
          • Raffaella Labbadia, MD
      • Barcelona, Spanien, 08035
        • Rekruttering
        • Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica
        • Ledende efterforsker:
          • Gema Ariceta, MD
        • Kontakt:
      • Barcelona, Spanien, 08950
        • Ikke rekrutterer endnu
        • Hospital Sant Joan De Deu Barcelona
        • Kontakt:
        • Ledende efterforsker:
          • Yolanda Calzada, MD
    • Stockholm County
      • Huddinge, Stockholm County, Sverige, SE-141 86

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 år til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Signed Informed Consent obtained from patient/parent/legal guardian/independent witness (depending on patient's age) before any trial-related procedures
  2. Highly sensitised patient with panel reactive antibodies (PRA) ≥80%
  3. Male or female patient between the age of 1 to 17 years (up to the day before the 18th birthday) at the time of screening
  4. Patient with end-stage renal disease (ESRD) and waiting for a renal transplant from a living or deceased donor
  5. Patient must be transplantable (including size mismatch) at the time of obtaining informed consent for trial participation
  6. Patients who have previously undergone desensitisation unsuccessfully with plasmapheresis/IVIg/anti-CD20 or have an anti-HLA antibody status deemed too difficult to make a successful desensitisation (judgement based on physicians' previous experience with similar patients)
  7. Positive crossmatch (XM) test determined by flow cytometry crossmatch (FCXM) and/or complement-dependent cytotoxicity crossmatch (CDCXM) tests against the donor. For the DD patients, if physical XM tests are not practically possible due to lack of time, patients may be included on a virtual crossmatch (vXM) predictive of a positive XM test.
  8. Willingness and ability to comply with the protocol as judged by the investigator

Exclusion Criteria:

  1. Previous treatment with imlifidase
  2. IVIg treatment within 28 days prior to imlifidase treatment
  3. Desensitisation treatment(s) within 1 month prior to the current transplantation
  4. Hypersensitivity to the active substance (imlifidase) or to any of the excipients and to other immunosuppressive drugs specified in the protocol
  5. Ongoing serious infections
  6. Present, or history of, thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP
  7. At the time of transplantation: severe other condition requiring treatment and close monitoring e.g. cardiac failure ≥ grade 4 (New York Heart Association), unstable coronary disease, active peripheral vascular disease, proven hypercoagulable conditions/events or oxygen dependent respiratory disease
  8. Malignancy within 3 years prior to transplantation
  9. ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients)
  10. Any other reason that, in the view of the investigator, precludes transplantation
  11. Breast feeding or pregnancy, if applicable
  12. Woman of fertile age and sexually active without adequate contraceptive measures to avoid pregnancy during the interventional trial period (i.e. up to 6 months after transplantation)
  13. Suspicion of Covid-19 infection or positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test
  14. Positive serology for human immunodeficiency virus (HIV)
  15. Clinical signs of hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), or Epstein Barr virus (EBV) infection
  16. Donor with positive serology for HIV, HBV, HCV or CMV to a patient with negative serology (mismatch serology). Mismatch serology for EBV in accordance with center specific standard procedures for transplantation of EBV negative recipients and at investigator's discretion.
  17. Clinically relevant active infection(s) as judged by the investigator
  18. Tuberculosis or history of tuberculosis
  19. Use of other investigational agents within 5 terminal elimination half-lives prior to the transplantation
  20. Contemporaneous participation in medical device studies
  21. Known mental incapacity or language barriers precluding patients'/parents'/legal guardians' adequate understanding of the informed consent information and the trial activities
  22. Inability by the judgement of the investigator to participate in the trial for any other reason

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Imlifidase

Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation.

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

Andre navne:
  • IdeS, HMED-IdeS

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatment
Tidsramme: From start of imlifidase administration to 24 hours

Immunoglobulins (IgG) including donor specific antibodies (DSAs) are rapidly and efficiently cleaved by imlifidase. A conversion of a positive to a negative XM will enable transplantation.

From start of imlifidase administration to 24 hours

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Transplantatoverlevelse (død censureret) op til 5 år efter transplantation
Tidsramme: Fra 6 måneder op til 5 år
Fra 6 måneder op til 5 år
Transplantationssvigtfri overlevelse op til 5 år efter transplantation
Tidsramme: Fra 6 måneder op til 5 år
Fra 6 måneder op til 5 år
Patientoverlevelse op til 5 år efter transplantation
Tidsramme: Fra 6 måneder op til 5 år
Fra 6 måneder op til 5 år
Andel af patienter med dialyseafhængighed op til 5 år efter transplantation
Tidsramme: Fra 6 måneder op til 5 år
Fra 6 måneder op til 5 år
Renal function up to 5 years after transplantation as assessed by estimated glomerular filtration rate (eGFR)
Tidsramme: From pre-dose imlifidase up to 5 years

eGFR is a measure of kidney function. Reduced kidney function is characterised by a decreased eGFR value.

From pre-dose imlifidase up to 5 years
Renal function up to 5 years after transplantation as assessed by serum/plasma creatinine levels
Tidsramme: From pre-dose imlifidase up to 5 years

Creatinine is a measure of kidney function. Reduced kidney function is characterised by an increased value.

From pre-dose imlifidase up to 5 years
Renal function up to 5 years after transplantation as assessed by serum/plasma cystatin C levels
Tidsramme: From pre-dose imlifidase up to 5 years

Cystatin C is a measure of kidney function. Reduced kidney function is characterised by an increased value.

From pre-dose imlifidase up to 5 years
Renal function up to 5 years after transplantation as assessed by proteinuria
Tidsramme: From pre-dose imlifidase up to 5 years

Proteinuria (protein/creatinine ratio in urine) is a measure of kidney function. Reduced kidney function is characterised by an increased value.

From pre-dose imlifidase up to 5 years
DSA levels up to 5 years after transplantation
Tidsramme: From pre-dose imlifidase up to 5 years

Donor specific antibodies (DSAs) are antibodies in the recipient directed against the transplanted organ.

From pre-dose imlifidase up to 5 years
Frequency of delayed graft function (DGF)
Tidsramme: From transplantation up 7 days after transplantation

DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019.

Frequency of patients having DGF in accordance with this definition will be presented.

From transplantation up 7 days after transplantation
Length of DGF
Tidsramme: From transplantation up 7 days after transplantation

DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019.

The duration of DGFs in accordance with this definition will be presented.

From transplantation up 7 days after transplantation
Imlifidase Pharmacokinetics (AUC)
Tidsramme: From pre-dose imlifidase up to Day 15

AUC = Area under the imlifidase plasma concentration versus time curve.

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (Cmax)
Tidsramme: From pre-dose imlifidase up to Day 15

Cmax = Maximum observed plasma concentration of imlifidase following dosing.

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (tmax)
Tidsramme: From pre-dose imlifidase up to Day 15

tmax = Time point for maximum observed plasma concentration of imlifidase following dosing

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (t1/2)
Tidsramme: From pre-dose imlifidase up to Day 15

t1/2 = Terminal half-life of imlifidase.

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (CL)
Tidsramme: From pre-dose imlifidase up to Day 15

CL = Clearance of imlifidase.

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacokinetics (Vz)
Tidsramme: From pre-dose imlifidase up to Day 15

Vz = Volume of distribution during the elimination phase

From pre-dose imlifidase up to Day 15
Imlifidase Pharmacodynamic (PD) profile up to 9 days after imlifidase treatment
Tidsramme: From pre-dose imlifidase up to Day 10

PD is assessed as serum concentrations of intact IgG and its fractions following infusion.

From pre-dose imlifidase up to Day 10
Immunogenicity profile of imlifidase up to 5 years after imlifidase treatment
Tidsramme: From pre-dose imlifidase up to 5 years

Immunogenicity is assessed as serum concentration of anti-imlifidase IgG (ADA).

From pre-dose imlifidase up to 5 years
Proportion of patients with biopsy- and serology (DSA)-confirmed AMR up to 5 years after transplantation
Tidsramme: From transplantation up to 5 years

Banff scores (Loupy et al. 2020) will be used for biopsy evaluation.

From transplantation up to 5 years
Proportion of patients with biopsy confirmed cell-mediated rejection (CMR) up to 5 years after transplantation
Tidsramme: From transplantation up to 5 years

Banff scores (Loupy et al. 2020) will be used for biopsy evaluation.

From transplantation up to 5 years

Andre resultatmål

Resultatmål
Tidsramme
Sikkerhed vurderet som andel af patienter med infusionsrelaterede reaktioner inden for 48 timer efter imlifidase-infusion
Tidsramme: Fra start af imlifidase-infusion op til 48 timer
Fra start af imlifidase-infusion op til 48 timer
Sikkerhed vurderet som andel af patienter med alvorlige eller alvorlige infektioner inden for 30 dage efter imlifidase -behandling
Tidsramme: Fra start af imlifidase -infusion op til 30 dage
Fra start af imlifidase -infusion op til 30 dage

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Operations, Hansa Biopharma AB

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

2. juni 2023

Primær færdiggørelse (Anslået)

28. februar 2027

Studieafslutning (Anslået)

31. august 2031

Datoer for studieregistrering

Først indsendt

23. februar 2023

Først indsendt, der opfyldte QC-kriterier

23. februar 2023

Først opslået (Faktiske)

3. marts 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 20-HMedIdes-21
  • 2022-500230-28-00 (Anden identifikator: EU Trial Number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .